Nanexa Past Earnings Performance

Past criteria checks 0/6

Nanexa's earnings have been declining at an average annual rate of -31.4%, while the Medical Equipment industry saw earnings growing at 22.9% annually. Revenues have been growing at an average rate of 35.2% per year.

Key information

-31.4%

Earnings growth rate

5.4%

EPS growth rate

Medical Equipment Industry Growth6.2%
Revenue growth rate35.2%
Return on equity-78.0%
Net Margin-126.9%
Next Earnings Update19 Feb 2025

Recent past performance updates

Recent updates

How Much Does Nanexa's (STO:NANEXA) CEO Make?

Dec 09
How Much Does Nanexa's (STO:NANEXA) CEO Make?

Revenue & Expenses Breakdown

How Nanexa makes and spends money. Based on latest reported earnings, on an LTM basis.


Earnings and Revenue History

OM:NANEXA Revenue, expenses and earnings (SEK Millions)
DateRevenueEarningsG+A ExpensesR&D Expenses
30 Sep 2451-64410
30 Jun 2453-67430
31 Mar 2460-71460
31 Dec 2359-76480
30 Sep 2352-43550
30 Jun 2347-49550
31 Mar 2335-55540
31 Dec 2227-59520
30 Sep 2224-54460
30 Jun 2219-50420
31 Mar 2218-42390
31 Dec 2118-36330
30 Sep 2119-31360
30 Jun 2122-27310
31 Mar 2122-25240
31 Dec 2021-22220
30 Sep 2018-19110
30 Jun 2013-18100
31 Mar 2011-1390
31 Dec 199-1380
30 Sep 197-1290
30 Jun 196-1180
31 Mar 194-1280
31 Dec 184-1180
30 Sep 184-970
30 Jun 184-960
31 Mar 184-860
31 Dec 173-860
30 Sep 173-860
30 Jun 172-850
31 Mar 172-750
31 Dec 162-650
30 Sep 162-640
30 Jun 162-640
31 Mar 162-540
31 Dec 152-440
30 Sep 151-220
30 Jun 150-210
31 Mar 150-100
31 Dec 140-100
30 Apr 141020

Quality Earnings: NANEXA is currently unprofitable.

Growing Profit Margin: NANEXA is currently unprofitable.


Free Cash Flow vs Earnings Analysis


Past Earnings Growth Analysis

Earnings Trend: NANEXA is unprofitable, and losses have increased over the past 5 years at a rate of 31.4% per year.

Accelerating Growth: Unable to compare NANEXA's earnings growth over the past year to its 5-year average as it is currently unprofitable

Earnings vs Industry: NANEXA is unprofitable, making it difficult to compare its past year earnings growth to the Medical Equipment industry (31%).


Return on Equity

High ROE: NANEXA has a negative Return on Equity (-78.04%), as it is currently unprofitable.


Return on Assets


Return on Capital Employed


Discover strong past performing companies

Company Analysis and Financial Data Status

DataLast Updated (UTC time)
Company Analysis2025/01/07 07:44
End of Day Share Price 2025/01/07 00:00
Earnings2024/09/30
Annual Earnings2023/12/31

Data Sources

The data used in our company analysis is from S&P Global Market Intelligence LLC. The following data is used in our analysis model to generate this report. Data is normalised which can introduce a delay from the source being available.

PackageDataTimeframeExample US Source *
Company Financials10 years
  • Income statement
  • Cash flow statement
  • Balance sheet
Analyst Consensus Estimates+3 years
  • Forecast financials
  • Analyst price targets
Market Prices30 years
  • Stock prices
  • Dividends, Splits and Actions
Ownership10 years
  • Top shareholders
  • Insider trading
Management10 years
  • Leadership team
  • Board of directors
Key Developments10 years
  • Company announcements

* example for US securities, for non-US equivalent regulatory forms and sources are used.

Unless specified all financial data is based on a yearly period but updated quarterly. This is known as Trailing Twelve Month (TTM) or Last Twelve Month (LTM) Data. Learn more here.

Analysis Model and Snowflake

Details of the analysis model used to generate this report is available on our Github page, we also have guides on how to use our reports and tutorials on Youtube.

Learn about the world class team who designed and built the Simply Wall St analysis model.

Industry and Sector Metrics

Our industry and section metrics are calculated every 6 hours by Simply Wall St, details of our process are available on .

Analyst Sources

Nanexa AB (publ) is covered by 2 analysts. 1 of those analysts submitted the estimates of revenue or earnings used as inputs to our report. Analysts submissions are updated throughout the day.

AnalystInstitution
Gonzalo Artiach CastanonABG Sundal Collier Sponsored
Fredrik ThorRedeye